[en] Pleural mesothelioma (PM) is a rare and aggressive cancer with a poor prognosis, primarily caused by asbestos exposure and originating from the mesothelial cells of the pleura. For almost two decades, the standard first-line treatment for unresectable PM has involved a combination of cisplatin or carboplatin with pemetrexed. More recently, immunotherapy with immune checkpoint inhibitors (ICIs) has emerged as a frontline option, especially for the sarcomatoid subtype. However, despite these advancements, the benefits remain limited, with only a subset of patients responding to ICIs and a modest median overall survival improvement. Consequently, a new treatment paradigm combining chemotherapy with ICIs is being explored in various clinical trials, although results have been disappointing so far. The underlying biological mechanisms driving this general lack of response remain poorly understood, with emerging evidence nevertheless pointing to the crucial influence of the tumor microenvironment.
In this context, this thesis project aimed to deepen our understanding of the immune landscape in PM, with a particular focus on tumor-associated macrophages (TAMs), using single-nucleus RNA sequencing of PM biopsies. Simultaneously, the project sought to develop innovative therapeutic strategies by exploring two approaches: re-programming monocytes with epigenetic modulators and evaluating the synergistic potential of metronomic chemotherapy (mCT) combined with doublet immunotherapy in preclinical models.
Through the snRNA-seq analysis of PM patient biopsies, the main immune cell types previously described in PM were identified, and the characterization of PM TAMs was significantly expanded. Notably, an association between hypoxic TAMs and poor survival in PM patients was identified. TGF-β3 emerged as a potential driver of the hypoxic TAM phenotype, suggesting novel therapeutic approaches. Moreover, comparative analysis with non-tumoral macrophages revealed a global angiogenic signature among TAMs, with CD93 and SPP1 identified as potential therapeutic targets.
In a complementary study, it was demonstrated that blood-derived monocytes exhibited inherent cytotoxic activity against PM cells, at a low level. Treatment with valproic acid (VPA), a histone deacetylase inhibitor, significantly enhanced this cytotoxicity as well as monocyte migration and their aggregation with tumor cells. Additionally, VPA down-regulated key receptors associated with an M2-like phenotype, such as CD163, CD206, and CD209, suggesting VPA as an interesting compound to improve PM treatment outcomes, through modulation of monocyte cytotoxicity.
Lastly, a preclinical study demonstrated that various chemotherapeutic agents administered on a metronomic schedule effectively reduced tumor growth in syngeneic preclinical PM models. Surprisingly, mice treated with a combination of ICIs and metronomic cisplatin and pemetrexed demonstrated heterogeneous responses, with stabilization of tumor growth observed in some cases. Notably, this variability in response did not correlate with differences in immune cell infiltration at the end of treatment, underscoring the necessity for further investigation into the underlying mechanisms driving this response variability.
Research Center/Unit :
GIGA-CME - GIGA Cancer-Cellular and Molecular Epigenetics - ULiège
Disciplines :
Oncology
Author, co-author :
Fontaine, Alexis ; Université de Liège - ULiège > TERRA Research Centre
Language :
English
Title :
Tumor microenvironment heterogeneity and novel therapeutic approaches in pleural mesothelioma
Alternative titles :
[fr] Hétérogénéité du microenvironnement tumoral et nouvelles approches thérapeutiques dans le mésothéliome pleural
Original title :
[en] Tumor microenvironment heterogeneity and novel therapeutic approaches in pleural mesothelioma
Defense date :
2024
Institution :
ULiège - Université de Liège [Gembloux Agro-Bio Tech], Gembloux, Belgium
Degree :
Doctorat en sciences agronomiques et ingénierie biologique
Promotor :
Willems, Luc ; Université de Liège - ULiège > GIGA > GIGA Cancer - Cellular and Molecular Epigenetics ; Université de Liège - ULiège > Département GxABT > Microbial technologies
President :
Richel, Aurore ; Université de Liège - ULiège > TERRA Research Centre > Chemistry for Sustainable Food and Environmental Systems (CSFES)
Jury member :
Herfs, Michael ; Université de Liège - ULiège > GIGA > GIGA Cancer - Experimental Pathology
Hamaïdia, Malik ; Université de Liège - ULiège > Département GxABT > Microbial technologies
Jean, Dider; Centre de Recherche des Cordeliers > Génomique fonctionnelle des tumeurs solides
Blanquart, Christophe; Université de Nantes > Immunomodulation du microenvironnement tumoral et immunothérapie des cancers thoraciques
Scherpereel, Arnaud; CHU de Lille - Centre Hospitalier Universitaire de Lille > Pneumology and Thoracic Oncology
Funders :
F.R.S.-FNRS - Fonds de la Recherche Scientifique Télévie Fondation Léon Fredericq
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.